These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Millions of stroke survivors across the world may soon have a new defense
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
